About Vanda Pharmaceuticals Inc.
https://www.vandapharma.comVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
CEO
Mihael H. Polymeropoulos
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 102
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:8.92M
Value:$66.66M
BLACKROCK INC.
Shares:8.14M
Value:$60.83M
VANGUARD GROUP INC
Shares:3.59M
Value:$26.81M
Summary
Showing Top 3 of 198
About Vanda Pharmaceuticals Inc.
https://www.vandapharma.comVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $56.26M ▲ | $84.59M ▼ | $-22.59M ▲ | -40.15% ▲ | $-0.38 ▲ | $-29.23M ▲ |
| Q2-2025 | $52.59M ▲ | $86.61M ▼ | $-27.21M ▲ | -51.73% ▲ | $-0.46 ▲ | $-32.87M ▼ |
| Q1-2025 | $50.04M ▼ | $91.07M ▲ | $-29.49M ▼ | -58.94% ▼ | $-0.5 ▼ | $-31.11M ▼ |
| Q4-2024 | $53.19M ▲ | $60.87M ▲ | $-4.91M ▲ | -9.24% ▲ | $-0.08 ▲ | $-8.31M ▲ |
| Q3-2024 | $47.65M | $56.1M | $-5.32M | -11.17% | $-0.09 | $-9.03M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $293.75M ▼ | $601.14M ▼ | $135.14M ▼ | $466M ▼ |
| Q2-2025 | $325.55M ▼ | $624.75M ▼ | $138.42M ▲ | $486.33M ▼ |
| Q1-2025 | $340.91M ▼ | $631.94M ▼ | $120.52M ▲ | $511.42M ▼ |
| Q4-2024 | $374.64M ▼ | $656.2M ▲ | $117.66M ▲ | $538.55M ▼ |
| Q3-2024 | $376.26M | $645.12M | $103.89M | $541.22M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-22.59M ▲ | $-31.63M ▼ | $21.36M ▲ | $-517K ▼ | $-10.96M ▲ | $-31.79M ▼ |
| Q2-2025 | $-27.21M ▲ | $-15.25M ▲ | $-15.27M ▼ | $-425K ▲ | $-30.81M ▼ | $-15.55M ▲ |
| Q1-2025 | $-29.49M ▼ | $-33.15M ▼ | $43.9M ▲ | $-1.32M ▼ | $9.48M ▲ | $-33.58M ▼ |
| Q4-2024 | $-4.91M ▲ | $-1.82M ▲ | $3.99M ▼ | $-155K ▼ | $1.82M ▲ | $-2.03M ▲ |
| Q3-2024 | $-5.32M | $-14.58M | $12.06M | $0 | $-2.46M | $-14.74M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Fanapt | $30.00M ▲ | $20.00M ▼ | $30.00M ▲ | $30.00M ▲ |
 Hetlioz | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
CEO
Mihael H. Polymeropoulos
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 102
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:8.92M
Value:$66.66M
BLACKROCK INC.
Shares:8.14M
Value:$60.83M
VANGUARD GROUP INC
Shares:3.59M
Value:$26.81M
Summary
Showing Top 3 of 198